Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug‐resistant gestational trophoblastic neoplasia: Four case reports and literature review

Abstract

AbstractBackgroundMultiple studies have confirmed that programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) is widely expressed in gestational trophoblastic neoplasia (GTN) tissues. Therefore, immune checkpoint inhibitors may be an option for the treatment of recurrent and drug‐resistant GTN.CaseFour patients with recurrent or drug‐resistant GTN who were treated with PD‐1/PD‐L1 checkpoint inhibitor agents combined with chemotherapy were reported. The mean age of recurrence was 45.8 years (35–56 years), including three cases of choriocarcinoma (CC) and one case of invasive mole (IM). International Federation of Gynecology and Obstetrics (FIGO) prognosis score: ≤6 (low risk) in one case, 7–12 (high risk) in one case, ≥13 (very high risk) in two cases. There were two cases of lung metastasis and one case of vulvar and inguinal lymph node metastasis. One of the four patients underwent total hysterectomy and one patient underwent resection of lung metastases. All the four patients received comprehensive treatment of immunotherapy combined with chemotherapy after relapse, among which one patient achieved complete response (CR), two patients achieved partial response (PR), and one patient developed progressive disease (PD). Three patients who achieved PR or CR were maintained by single agent immunotherapy after combination therapy, and there was no disease recurrence during follow‐up. One patient with PD also achieved CR after using salvage chemotherapy after recurrence, and there was no disease recurrence during follow‐up. During the treatment, four patients had different degrees of immune‐related adverse reactions, all of which were grade I‐II, and no severe adverse reactions were found.ConclusionImmune checkpoint inhibitors combined with chemotherapy has an impressive therapeutic effect on recurrent or drug‐resistant GTN with mild adverse reactions, which can be used as a treatment option for such patients. However, due to the lack of large sample data support, the specific time and treatment course of its use, long‐term use of adverse reactions and whether it affects fertility function remain to be solved.